Profile data is unavailable for this security.
About the company
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
- Revenue in HKD (TTM)6.65bn
- Net income in HKD576.41m
- Incorporated2003
- Employees5.27k
- LocationLuye Pharma Group LtdNo.15 Chuangye Road, High-Tech ZoneYANTAI 264003ChinaCHN
- Phone+86 5 356717618
- Fax+86 5 356717718
- Websitehttps://www.luye.cn/lvye/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Shineway Pharmaceutical Group Ltd | 4.89bn | 1.05bn | 7.98bn | 3.44k | 6.95 | 1.05 | 6.49 | 1.63 | 1.39 | 1.39 | 6.47 | 9.21 | 0.5073 | 1.44 | 6.31 | 1,422,586.00 | 10.89 | 8.03 | 14.15 | 9.77 | 75.15 | 74.55 | 21.47 | 17.87 | 2.98 | -- | 0.0411 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Everest Medicines Ltd | 136.29m | -913.92m | 8.44bn | 432.00 | -- | 1.55 | -- | 61.96 | -2.92 | -2.92 | 0.4353 | 16.84 | 0.0203 | 2.25 | 4.57 | 315,484.80 | -13.63 | -30.52 | -15.06 | -33.14 | 72.67 | -- | -670.57 | -5,745.25 | 8.29 | -- | 0.0979 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Beijing Tong Ren Tang Chinese Medicine | 1.52bn | 540.39m | 8.50bn | 798.00 | 15.74 | 2.20 | 12.64 | 5.58 | 0.6456 | 0.6456 | 1.82 | 4.62 | 0.3522 | 0.6449 | 2.31 | 1,910,959.00 | 13.64 | 16.71 | 15.50 | 18.75 | 68.67 | 69.88 | 38.73 | 40.72 | 8.59 | -- | 0.0317 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
| Cansino Biologics Inc | 373.57m | -1.60bn | 9.33bn | 1.49k | -- | 0.885 | -- | 24.98 | -6.50 | -6.50 | 1.51 | 23.11 | 0.0332 | 2.37 | 0.4619 | 250,048.10 | -18.93 | -4.27 | -26.69 | -5.60 | -253.78 | -- | -569.97 | -27.72 | 1.86 | -- | 0.3381 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Shanghai Henlius Biotech Inc | 5.84bn | 590.93m | 9.35bn | 3.64k | 15.86 | 3.94 | 9.54 | 1.60 | 1.08 | 1.08 | 10.70 | 4.37 | 0.5731 | 1.95 | 9.10 | 1,605,339.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| Lepu Biopharma Co Ltd | 243.89m | -23.91m | 9.67bn | 429.00 | -- | 9.97 | 123.94 | 39.67 | -0.0144 | -0.0144 | 0.147 | 0.5849 | 0.0917 | 1.06 | 1.62 | 568,499.60 | -1.23 | -- | -1.91 | -- | 87.45 | -- | -13.45 | -- | 0.7201 | 0.1388 | 0.4549 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
| AIM Vaccine Co Ltd | 1.29bn | -1.41bn | 9.95bn | 1.62k | -- | 2.53 | -- | 7.75 | -1.16 | -1.16 | 1.06 | 3.26 | -- | -- | -- | 791,337.80 | -- | -- | -- | -- | 75.88 | -- | -164.24 | -- | 0.7583 | -14.04 | 0.3158 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| InnoCare Pharma Ltd | 799.28m | -683.18m | 10.18bn | 1.09k | -- | 1.16 | -- | 12.74 | -0.4051 | -0.4051 | 0.4737 | 4.39 | 0.073 | 1.39 | 3.39 | 733,956.60 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| Keymed Biosciences Inc | 383.22m | -388.91m | 11.32bn | 897.00 | -- | 3.50 | -- | 29.53 | -1.49 | -1.49 | 1.45 | 11.55 | 0.0906 | 0.7314 | 26.14 | 427,221.80 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| SciClone Pharmaceuticals (Holdings) Ltd | 3.42bn | 1.21bn | 11.44bn | 1.05k | 9.77 | 3.11 | 8.34 | 3.35 | 1.86 | 1.86 | 5.25 | 5.85 | 0.7585 | 3.56 | 3.83 | 3,252,525.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 33.70 | 0.01 | 22.98 | 14.76 | 17.50 | 31.16 | 15.96 | 25.65 | -- |
| Luye Pharma Group Ltd | 6.65bn | 576.41m | 11.47bn | 5.27k | 19.81 | 0.846 | 8.54 | 1.73 | 0.154 | 0.154 | 1.78 | 3.61 | 0.247 | 2.42 | 3.60 | 1,261,541.00 | 2.17 | 2.80 | 3.56 | 4.45 | 68.44 | 70.53 | 8.78 | 10.39 | 1.21 | 3.10 | 0.3931 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.81bn | 2.16bn | 11.58bn | 4.62k | 5.37 | 1.35 | 4.76 | 1.70 | 2.45 | 2.45 | 7.74 | 9.76 | 0.5111 | 3.62 | 4.09 | 1,475,160.00 | 15.07 | 8.03 | 24.46 | 11.81 | 79.21 | 79.97 | 29.48 | 20.80 | 1.30 | 11.16 | 0.2475 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| SSY Group Ltd | 6.46bn | 1.32bn | 14.58bn | 5.60k | 11.09 | 2.10 | 8.34 | 2.26 | 0.4427 | 0.4427 | 2.17 | 2.33 | 0.5637 | 3.00 | 3.01 | 1,154,109.00 | 11.59 | 10.51 | 15.58 | 14.03 | 56.01 | 58.72 | 20.57 | 18.62 | 1.60 | 29.61 | 0.317 | 38.56 | 0.4505 | 9.10 | 17.44 | 7.66 | 3.94 | 13.56 |
Data as of May 10 2024. Currency figures normalised to Luye Pharma Group Ltd's reporting currency: Hong Kong Dollar HKD
15.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 10 Aug 2023 | 184.79m | 4.91% |
| UBS Asset Management Switzerland AGas of 24 Apr 2024 | 138.36m | 3.68% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 70.39m | 1.87% |
| Zhong Geng Fund Management Co. , Ltd.as of 30 Jun 2023 | 61.76m | 1.64% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 38.58m | 1.03% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 24.35m | 0.65% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 21.42m | 0.57% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2023 | 17.99m | 0.48% |
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 8.30m | 0.22% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 6.49m | 0.17% |
More ▼
Data from 30 Jun 2023 - 02 May 2024Source: FactSet Research Systems Inc.
